Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...

A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their ...

Novo Nordisk shares dropped 5% in early trading on Monday after Eli Lilly released new trial data showing its weight loss ...

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

May 12 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Sunday its drug Zepbound was superior to Novo Nordisk's (NOVOb.CO), opens new tab Wegovy across five weight-loss targets such as ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

Novo Nordisk NVO announced a significant partnership with Septerna SEPN, a U.S.-based biotech company, valued at up to $2.2 billion, to tap the growing obesity treatment market. F ...